Methylphenidate (MPD) is clinically effective in treating the symptoms of attention-deficit hyperactivity disorder; however, its relatively widespread availability has raised public health concerns on nonmedical use of MPD among certain adult populations. Most preclinical studies investigate whether presumed therapeutically relevant doses of MPD alter sensitivity to the reinforcing effects of other drugs, but it remains unclear whether doses of MPD likely exceeding therapeutic relevance impact the subsequent reinforcing effects of drugs. To begin to address this question, the effect of prior MPD self-administration (0.56 mg/kg/infusion) on the subsequent reinforcing effects of methamphetamine (METH, 0.032 or 0.1 mg/kg/infusion) was investigated in male Sprague-Dawley rats. For comparison, it was also determined whether prior experimenter-administered MPD, injected daily at a presumed therapeutically relevant dose (2 mg/kg), altered the subsequent reinforcing effects of METH. Results indicated that, under the current conditions, only a history of MPD self-administration increased sensitivity to the subsequent reinforcing effects of METH. Furthermore, MPD did not impact food-maintained responding, suggesting that the effect of MPD might be specific to drug reinforcers. These data suggest that short-term, nonmedical use of MPD might alter the positive reinforcing effects of METH in a manner relevant to vulnerability to drug use in humans. Behavioural Pharmacology 25:758-765
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that affects an estimated 9.0% of American children between the ages of 13 and 18 years (Merikangas et al., 2010) and 4.1% of American adults aged 18 years or older (Kessler et al., 2005) . Although the etiology of the disorder is not well understood, treatment of ADHD generally involves pharmacotherapy with psychostimulants, such as methylphenidate (MPD). MPD, like cocaine, inhibits the dopamine (DA) transporter (DAT; Ritz et al., 1987) and thereby increases extracellular DA (Hurd and Ungerstedt, 1989; Butcher et al., 1991) , which in turn binds to various dopaminergic receptor subtypes. Indeed, MPD is one of the most commonly prescribed psychostimulants in the USA (Zito et al., 2000; Olfson et al., 2002; Kaye and Darke, 2012) , and because ADHD often persists into adulthood (Wilens et al., 1995; Wilens and Dodson, 2004; Spencer et al., 2007) , prolonged treatment with medications like MPD is common (Kolar et al., 2008) .
Although medications, such as MPD, are clinically effective in treating the symptoms of ADHD, their relatively widespread availability has raised public health concerns Kaye and Darke, 2012) with regard to their abuse potential and nonmedical use among adults in general, as well as among college students in particular (Teter et al., 2003; DeSantis et al., 2008; Johnston et al., 2012) . For instance, one study reported that 7.5% of college students reported pharmaceutical stimulant misuse (including MPD) within the past 30 days (Weyandt et al., 2009 ; also see Dupont et al., 2008 , and for a review see Kaye and Darke, 2012) . A wealth of both animal and human literature has reported that MPD produces subjective and reinforcing effects similar to those produced by other drugs of abuse like cocaine and amphetamine (for review see Kollins et al., 2001) , providing evidence for the potential abuse liability of MPD. Furthermore, a number of studies exist in the literature describing intranasal or intravenous misuse of MPD (Levine et al., 1986; Jaffe, 1991; Parran and Jasinski, 1991; Garland 1998; Massello and Carpenter, 1999; Morton and Stockton, 2000; Gautschi and Zellweger, 2006) .
Despite the misuse of prescription MPD among certain adult populations (Teter et al., 2006; Kaye and Darke, 2012) , the majority of clinical studies have focused on whether long-term use of clinically relevant doses of MPD leads to an increase in the risk for a subsequent substance abuse disorder. For instance, in clinical studies involving ADHD patients, results suggest that treatment does not increase (Biederman et al., 2008; Mannuzza et al., 2008) , and may even decrease (Biederman et al., 1999; Barkley et al., 2003) , the likelihood of developing a substance abuse disorder. However, one study showed an increased risk for tobacco and cocaine use among adults with ADHD who were treated with stimulants as children (Lambert and Hartsough, 1998) . These mixed results may be due to numerous factors including differences in treatment (i.e. duration, dosing) and diagnoses as well as comorbidities with other disorders among human patients with ADHD.
In the majority of preclinical studies, adolescent animals were treated with doses thought to mimic clinically relevant doses of MPD for periods ranging from a few weeks to several months and were subsequently tested during adulthood for altered sensitivity to the effects of pharmacologically similar drugs such as cocaine. Of these studies of adolescent rats treated with MPD, some have shown increased sensitivity to the reinforcing (i.e. selfadministration) effects of cocaine (Brandon et al., 2001; Schenk and Izenwasser, 2002; Crawford et al., 2011) , whereas at least one study has shown decreased sensitivity to the reinforcing effects of cocaine (Thanos et al., 2007) . In nonhuman primates treated with a dose of MPD that mimics therapeutic levels, there was no difference in cocaine self-administration, compared with those treated with placebo (Gill et al., 2012) .
MPD diversion and misuse appears to be most prevalent and problematic among adult populations (Teter et al., 2006; Kaye and Darke, 2012) ; however, there is a paucity of data on the relationship between short-term, large doses of MPD and subsequent sensitivity to the abuserelated effects of other drugs. In the available literature, some clinical data suggest that people who misuse stimulant medication such as MPD are more likely to misuse/abuse a variety of other drugs (e.g. marijuana, hallucinogens, cocaine; Substance Abuse and Mental Health Services Administration, 2009; Sweeney et al., 2013) . Furthermore, a recent study demonstrated that short-term exposure to a large dose of MPD (i.e. 5 days of MPD self-administration) enhanced the sensitivity to the reinforcing effects of amphetamine (Calipari et al., 2013) . The current study extends the findings of these studies to examine the effects of short-term MPD selfadministration on the subsequent reinforcing effects of two doses of methamphetamine (METH). Thus, the goals of the current study were to examine (i) whether a large dose of MPD (as observed in intravenous use; Levine et al., 1986; Parran and Jasinski, 1991; Morton and Stockton, 2000; Gautschi and Zellweger, 2006) impacts the subsequent reinforcing effects of METH, and (ii) whether MPD alters the subsequent reinforcing effects of a nondrug reinforcer (i.e. food). Finally, and for comparison, experimenter-administered MPD, administered at a relatively small dose that is thought to reflect therapeutic levels (Gerasimov et al., 2000; Brandon et al., 2001) , was also examined for its subsequent impact on the effects of METH.
Methods Subjects
A total of 60 male Sprague-Dawley rats [275-300 g; Charles River Breeding Laboratories (Raleigh, North Carolina, USA)] were housed individually and maintained in a temperature and humidity controlled environment on a 14 : 10 h light/dark cycle with free access to water (see Table 1 for experimental groups). Twentyfour hours before the initiation of operant training, all rats were food-restricted to 90% of their free-feeding body weight for the duration of the experiments (with the exception of recovery time after surgery). All experiments were approved by the University of Utah Institutional Animal Care and Use Committee, in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Apparatus
All experimental sessions were conducted in an operant chamber (30.5 × 25.5 × 30.5 cm; Coulbourn Instruments, Allentown, Pennsylvania, USA) located within a sound-attenuating cubicle (79 × 53 × 53 cm; Coulbourn Instruments). Each chamber was equipped with a food pellet hopper, two retractable levers, and a house light. An infusion pump connected to a liquid swivel suspended outside of the operant chamber delivered drug or saline through a polyethylene tube located within a spring leash tethered to a rat.
Food training
Before surgery, rats were trained to lever press for food under a fixed ratio (FR) 1 schedule of reinforcement, whereby pressing on either lever resulted in the delivery of a food pellet. In daily 1-h sessions, rats could receive a maximum of 100 pellets. When at least 50 pellets were received in a session, only responding on the active lever (for some rats the active lever was the left lever and for others, the right lever) was reinforced. Responses on the inactive lever were counted but had no programmed consequence. Food training was complete after the rats received at least 50 pellets in each of three consecutive sessions, while responding under the FR1 schedule (this training required approximately five to eight sessions).
Surgery
Rats were surgically implanted with a chronic indwelling jugular catheter (constructed in the laboratory as described previously, Frankel et al., 2011) in the right jugular vein, under ketamine : xylazine (90 : 7 mg/kg, intraperitoneally) anesthesia. The outlet of the catheter was implanted subcutaneously in the back, and the free end of the Silastic tubing was inserted ∼ 25 mm into the right jugular vein and secured to the surrounding tissue with sutures. Each rat received flunixin meglumine (subcutaneously) on the day Impact of prior MPD on the reinforcing effects of METH Baladi et al. 759 of the surgery. Immediately after surgery and daily thereafter, catheters were infused with 0.05 ml heparinized saline before the start of each session, and with 0.1 ml of the antibiotic cefazaolin followed by 0.05 ml heparinized saline and heparinized glycerol after the completion of each session. If at any point during the experiment the catheter leaks or abnormal shifts in self-administration behavior were observed, rats received xylazine through the catheter. Rats with patent catheters exhibited clear loss of muscle tone within a few seconds of the intravenous injection. Data collected from animals with nonpatent catheters were excluded from the data analyses (data from three rats were excluded). All rats were allowed to recover for a minimum of 3 days after surgery before the start of self-administration sessions.
Drug self-administration (experiment 1)
First, all rats were tested in daily 1-h sessions, during which illumination of the house light signaled availability of intravenous MPD (0.56 mg/kg/infusion, Marusich et al., 2010) or saline. A single response on the active lever resulted in the delivery of drug or saline (infusion duration 5-6 s, corresponding to 0.01-0.02 ml). Each infusion was followed by a 20-s timeout during which the chamber was dark and lever presses had no programmed consequence. Rats self-administered either MPD or saline for seven consecutive sessions, a sufficient period to allow for stabilization of responding, defined as three consecutive sessions in which the mean number of infusions for an individual rat did not change by more than 20% and there was no increasing or decreasing trend in overall group mean responding. After the 7-day period and to examine whether MPD history altered food-maintained responding, rats were placed in the operant chamber for daily 1-h sessions for 14 days and allowed to respond for food under the same schedule of reinforcement as described under food training (i.e. FR1 schedule of reinforcement, response on active lever delivered a food pellet, maximum of 100 pellets). Although all rats earned 100 food pellets after the first session, they were given 14 days of food-maintained responding to control for the number of days between MPD and METH across experiments. Subsequently, and to assess the influence of drug history on the reinforcing effects of METH, rats were allowed to selfadminister either METH (0.032 or 0.1 mg/kg/infusion) or saline, depending on the group. The conditions for METH self-administration were identical to those for MPD self-administration, with the exception that the duration of METH self-administration sessions was 8 h (i.e. a duration thought to better model METH-taking behaviors in humans; Kitamura et al., 2006; Krasnova et al., 2010) .
Pretreatment studies (experiment 2)
A separate study investigated the influence of an experimenter-administered dose of MPD, thought to reflect therapeutic levels (Gerasimov et al., 2000; Brandon et al., 2001) , or saline on the subsequent reinforcing effects of METH. Rats were administered either MPD (2 mg/ kg/day, intraperitoneally) or saline for seven consecutive days. Subsequently, rats were food-trained and surgically implanted with catheters (as described above). Fourteen days after the last MPD administration (i.e. the same number of days between the last MPD exposure and the first METH self-administration day in the above studies), rats were allowed to self-administer either METH (0.1 mg/ kg/infusion) or saline for seven consecutive days under the same conditions as described above.
Drugs ( )-Methamphetamine hydrochloride and methylphenidate hydrochloride (Research Triangle Institute, Research Triangle Park, North Carolina, USA) were dissolved in 0.9% sterile saline, with the dose described as the free-base form. Ketamine (Hospira Inc., Lake Forest, Illinois, USA) and xylazine (Sigma-Aldrich, St. Louis, Missouri, USA) were used to anesthetize the animals. The antibiotic cefazolin (10 mg/ml; Schein Pharmaceutical, Florham Park, New Jersey, USA) was dissolved in heparinized saline (63.33 U/ml; Sigma-Aldrich). Flunixin meglumine (1.1 mg/kg; MWI Veterinary Supply, Meridian, Idaho, USA) was used for postsurgical analgesia.
Data analyses
Self-administration data are expressed as the mean ( SEM) reinforcers earned and are plotted as a function of session. Dose-response curves represent the mean ( SEM) number of infusions or intake during the last three sessions for each dose of drug. For the saline data point, the mean ( SEM) number of infusions during the last three sessions was averaged across the two experiments in which the rats had prior MPD or saline reinforcement. Statistical analyses were carried out with an analysis of variance with post-hoc Bonferroni's tests for multiple comparisons. For all tests, significance was set at P less than 0.05.
Results

Experiment 1
Prior MPD self-administration increased and decreased subsequent responding for METH when administered at doses of 0.032 mg/kg/infusion ( Fig. 1) and 0.1 mg/kg/ infusion (Fig. 2) , respectively, compared with METH selfadministration in rats with no drug history. Furthermore, prior MPD self-administration did not alter subsequent food-maintained responding. Specifically, the results presented in Figs 1a and 2a illustrate the food and saline/MPD components of the experimental paradigm. For clarity, only the last three sessions of each food component are shown. In the first food component, the rate of acquisition for foodmaintained responding did not differ between groups or across experiments. In the subsequent self-administration component, responding maintained by MPD (0.56 mg/kg/ infusion) was greater than that by saline during sessions 5-7. In the second food component, prior MPD selfadministration did not alter subsequent food-maintained responding (i.e. both in terms of the number of food pellets earned and the time required to earn) between groups. For instance, the mean amount of time in minutes ( SEM) required to earn 100 or near 100 food pellets in the first session did not vary over 14 daily sessions [ Fig. 1a ; session 1: saline/saline 6.8 min ( 0.4), saline/METH 6.6 min ( 0.5), MPD/METH 6.9 min ( 0.3); session 14: saline/saline 7.0 min ( 0.3), saline/METH 6.4 min ( 0.5), MPD/METH 7.1 min ( 0.3)]. Finally, the results in Fig. 1b show that prior MPD exposure increased subsequent levels of METH self-administration when METH was available at a dose of 0.032 mg/kg/infusion, a dose that was not readily self-administered by rats previously exposed to saline. However, in contrast to the observations from Fig. 1b , the results presented in Fig. 2b indicate that prior MPD selfadministration decreased subsequent levels of METH selfadministration when METH was available at a dose of 0.1 mg/kg/infusion.
Dose-response curves for infusions and METH intake
were generated from the data presented in Figs 1b and 2b by averaging the last three sessions of METH selfadministration ( Fig. 3 ). Among rats with no drug history, there was a dose-dependent increase in the mean number of infusions ( Fig. 3a, open squares) . However, among rats with prior MPD self-administration, there was a dose-dependent decrease in the mean number of infusions ( Fig. 3a, gray  triangles) . These data suggest that among rats with a history of prior MPD self-administration, the dose-response curve for METH infusions shifts leftward and upward, compared with rats with no MPD history ( Fig. 3a ; see below for additional discussion). The corresponding dose-response curves for METH intake indicate that among rats with no drug history, there was a dose-dependent increase in the average METH intake (Fig. 3b, open squares) . However, among rats with prior MPD self-administration, the mean METH intake was similar between the two doses ( Fig. 3b , gray triangles).
Experiment 2 Figure 4 shows that prior experimenter-administered MPD (2 mg/kg/day for 7 days, intraperitoneally) did not impact the rate of acquisition for food-maintained responding (only the last three sessions of a 14-day food component are shown) or subsequent levels of METH self-administration. For example, responding maintained by METH (0.1 mg/kg/infusion) was greater than that by saline, and there was no difference in the number of infusions received by rats treated previously with either saline or MPD (Fig. 4, compare squares and triangles) . The mean ( SEM) number of infusions during the last three sessions for METH or saline was as follows: saline/saline 3 ( 0.5), saline/METH 61 ( 14.4), and MPD/METH 60 ( 7.0); the mean ( SEM) drug intakes (mg/kg) during the last three sessions for METH were as follows: saline/ METH 6.0 ( 1.4) and MPD/METH 6.0 ( 0.7).
Discussion
The major finding of the current study is that, under the current conditions, a history of MPD self-administration appears to increase the subsequent reinforcing effects of METH. Of significance is that, although the duration of MPD self-administration was relatively short (i.e. 7 days), it enhanced the reinforcing effects of METH long (i.e. 14 days) after the cessation of MPD. These findings in rats are similar to the effects reported by Calipari et al. (2013) , where prior MPD reinforcement increased responding for amphetamine. Furthermore, in the current study, prior experimenter-administered MPD did not alter subsequent METH self-administration, compared with rats with no drug history. Taken together, these data indicate that short-term, nonmedical use (i.e. large doses) of MPD might increase the sensitivity of individuals to the abuse-related effects of METH.
Drug self-administration data are typically plotted as reinforcers earned as a function of drug dose, and the curve is best described as an inverse U-shaped curve (although the shape can depend on the schedule of reinforcement). In the self-administration curve, increased or decreased sensitivity to the reinforcing effects of drugs is evident by a leftward/ upward or a rightward/downward shift, respectively. In the current study and among rats with no drug history, there was a dose-dependent increase in the mean number of infusions ( Fig. 3a, open squares) , consistent with findings that this represents the ascending limb of the inverted U-shaped dose-response curve associated with METH selfadministration, with its peak at 0.1 mg/kg/infusion (see Stefanski et al., 1999) . However, among rats with prior MPD self-administration, there was a dose-dependent decrease (corresponding to the descending limb of the dose-response curve, with the peak at 0.032 mg/kg/infusion) in the mean number of infusions (Fig. 3a, gray triangles) . These data are consistent with the possibility that among rats with prior MPD self-administration, the U-shaped dose-response curve for METH infusions shifted leftward and upward, compared with rats with no drug history. In contrast, the dose-effect curve for drug intake in mg/kg as a function of the unit dose of drug is typically a monotonic increasing function. Among rats with no drug history, there was a dosedependent increase in the average METH intake (Fig. 3b , open squares). However, among rats with prior MPD selfadministration, the average METH intake was similar between the two doses, reflecting the top of the monotonic function and a shift leftward compared with rats with no drug history (Fig. 3b, gray triangles) .
The underlying mechanism(s) by which administration of MPD might alter sensitivity to METH remains unclear. MPD binds to DAT and increases extracellular concentrations of DA (Schweri et al., 1985; Kuczenski and Segal, 1997) , which, in turn, binds to a number of DA receptor subtypes (i.e. D1, D2, and D3) that are important in mediating the behavioral effects of MPD (Botly et al., 2008) . Moreover, ex-vivo voltammetry studies have demonstrated that MPD self-administration increases DAT activity in the nucleus accumbens, compared with control rats (Calipari et al., 2013 (Calipari et al., , 2014 . Thus, it might be reasonable to speculate that MPD-induced increases in DAT activity (i.e. DA clearance) leads to a reduction in extracellular DA, compensatory upregulation of postsynaptic DA receptors, and increased sensitivity to drugs acting indirectly at those receptors (i.e. METH). In support of the possibility that increased sensitivity of MPD-treated rats to the reinforcing effects of METH is related to increased expression/activity of DA receptors, rats treated with drugs like MPD are more sensitive to the effects of direct-acting D2/D3 agonists (Collins et al., 2011) and the expression of DA receptor subtypes important in mediating the effects of MPD is greater, under some conditions (Thanos et al., 2007; Collins et al., 2011) .
Although this study is not the first to describe differences in the reinforcing properties of drugs following substitution from different maintenance drugs, including MPD (e.g. Brandon et al., 2001; Thanos et al., 2007; Calipari et al., 2013) , it is the first to address systematically the impact of varying drug and reinforcement histories on the capacity of METH to function as a reinforcer. That is, two conditions of MPD were evaluated, a small dose purportedly reflecting a therapeutic dose and a larger dose that might exceed therapeutic relevance, and only the larger dose of MPD increased the subsequent reinforcing effects of METH. In addition, a history of MPD self-administration did not impact responding maintained by a nondrug reinforcer (i.e. food; Figs 1a and 2a) , highlighting that MPD selectively alters the reinforcing properties of at least some drug reinforcers such as METH. Other studies have demonstrated that a history of drug reinforcement impacts subsequent reinforcing effects of drugs and not food (Collins and Woods, 2007) .
Although not tested in the current study, future studies might address whether a history of MPD reinforcement selectively alters the subsequent reinforcing effects of amphetamines. Previous studies, for example, have demonstrated that a history of MPD self-administration selectively enhances the reinforcing effects of amphetamine, but not cocaine (Calipari et al., 2013; Calipari et al., 2014) , suggesting that prior MPD self-administration does not similarly impact responding maintained by all drugs acting at DAT. In this regard, MPD selfadministration might change DA or even non-DA neurotransmitter systems (e.g. norepinephrine) in a manner that selectively alters the reinforcing effects of DA releasers, such as METH, but not DA blockers.
Finally, the current findings might suggest that prior exposure to nonmedicinal MPD sensitizes animals to the reinforcing effects of drug reinforcers. However, it is reasonable to speculate that sensitization alone does not account for the differences in METH self-administration because experimenter-administered MPD failed to alter subsequent METH self-administration ( Fig. 4) , as would have been expected if MPD exposure had been sufficient to sensitize the rats to the reinforcing effects of METH. In addition, even when a larger, experimenteradministered dose of MPD was used in another study (i.e. two injections of 5 mg/kg/day for 14 days, Calipari et al., 2013) , the subsequent reinforcing effects of amphetamine were not altered. Thus, although it seems unlikely that increasing the dose of experimenteradministered MPD would impact sensitivity to METH self-administration, future studies might vary the dose and route of administration.
In summary, misuse and abuse of prescription drugs, including medications such as MPD, have increased in recent years among certain adult populations (for review see Wilens et al., 2008; Bogle and Smith, 2009 ). There is still much to be learned with regard to interactions among drug history, sensitivity to drugs, and DA systems. The current study provides evidence that suggests that shortterm use of large doses of MPD might confer long-lasting changes to DA systems that impact subsequent sensitivity to the abuse-related effects of METH.
